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Abstract
Background: Antimicrobial peptides are present in animals, plants and microorganisms and play a fundamental
role in the innate immune response. Gomesin is a cationic antimicrobial peptide purified from haemocytes of the
spider Acanthoscurria gomesiana. It has a broad-spectrum of activity against bacteria, fungi, protozoa and tumour
cells. Candida albicans is a commensal yeast that is part of the human microbiota. However, in
immunocompromised patients, this fungus may cause skin, mucosal or systemic infections. The typical treatment
for this mycosis comprises three major categories of antifungal drugs: polyenes, azoles and echinocandins;
however cases of resistance to these drugs are frequently reported. With the emergence of microorganisms that
are resistant to conventional antibiotics, the development of alternative treatments for candidiasis is important. In
this study, we evaluate the efficacy of gomesin treatment on disseminated and vaginal candidiasis as well as its
toxicity and biodistribution.
Results: Treatment with gomesin effectively reduced Candida albicans in the kidneys, spleen, liver and vagina of
infected mice. The biodistribution of gomesin labelled with technetium-99 m showed that the peptide is captured
in the kidneys, spleen and liver. Enhanced production of TNF-a, IFN-g and IL-6 was detected in infected mice
treated with gomesin, suggesting an immunomodulatory activity. Moreover, immunosuppressed and C. albicans-
infected mice showed an increase in survival after treatment with gomesin and fluconazole. Systemic
administration of gomesin was also not toxic to the mice
Conclusions: Gomesin proved to be effective against experimental Candida albicans infection. It can be used as an
alternative therapy for candidiasis, either alone or in combination with fluconazole. Gomesin’s mechanism is not
fully understood, but we hypothesise that the peptide acts through the permeabilisation of the yeast membrane
leading to death and/or releasing the yeast antigens that trigger the host immune response against infection.
Therefore, data presented in this study reinforces the potential of gomesin as a therapeutic antifungal agent in
both humans and animals.
Background
Antimicrobial peptides (AMPs) are components of the
innate immune system of vertebrates and invertebrates,
having a broad-spectrum activity against bacteria, fungi,
viruses and protozoa [1]. In general, AMPs are small
molecules with 1 to 10 kDa of molecular mass and exhi-
bit a high content of basic amino acids, which results in
an overall positive net charge. AMPs also usually have
an amphipathic structure. Thus, while the positive
charges of basic amino acids facilitate interaction with
the negative charges of the phospholipids of biological
membranes, the hydrophobic amino acids facilitate the
insertion of AMPs into the membrane, which will even-
tually lead to lysis of the microorganisms. Some AMPs
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can act on internal targets, such as the inhibition of
nucleic acid and/or protein synthesis [1,2]. Alternatively,
some AMPs selectively boost the host immune response
through the regulation of the production of proinflam-
matory cytokines and chemokines and by promoting the
chemotaxis of T cells, monocytes, neutrophils and eosi-
nophils. They can also effect dendritic cell differentia-
tion and stimulate angiogenesis [3].
Gomesin is a cationic AMP isolated from haemocytes
of the tarantula spider Acanthoscurria gomesiana[4].
This peptide contains 18 amino acids and two disul-
phide bridges and adopts a b-hairpin structure [5]. The
disulphide bridges provide stability in mammalian
serum and resistance to proteolysis [6]. Gomesin exerts
a strong microbicidal activity against Gram-positive and
Gram-negative bacteria, filamentous fungi, yeast, para-
sites and tumour cells through a mechanism of pore for-
mation or “detergent like” action [4,7-9].
Candidiasis is an infection caused by fungi from the
genus Candida and can affect the skin, eyes, oral cavity,
oesophagus, gastrointestinal tract, vagina and vascular
system of humans. Most infections occur in patients
who are immunocompromised or debilitated [10]. Vul-
vovaginal candidiasis is the most common form of
mucosal disease, affecting up to 75% of women (review
by [11]). In Brazil, candidiasis has become a public
health problem. It is the 3rd leading cause of death from
systemic mycosis in AIDS-negative patients. Records
indicate an increase in mortality from an annual average
of 39 deaths between 1996 and 1998 to 54 between
2005 and 2006. Taking in account the deaths of AIDS
patients with underlying cases of candidiasis, the disease
is the 2nd leading cause of death from systemic mycosis,
with 1,780 deaths in Brazil from 1996 to 2006 [12].
Nosocomial candidiasis is also a public problem in Bra-
zil [13]. In the USA, Candida species are the fourth
leading cause of nosocomial bloodstream infections in
several hospitals and the mortality from 1997 to 2003
was approximately 0.4 deaths per 100,000 population
per year (review by [14,15]). The leading treatment of
Candida infections is done with polyenes (amphotericin
and liposomal amphotericin), azoles (fluconazole and
voriconazole) and echinocandins (caspofungine) [16].
Regardless of which antifungal drug is used, there is fre-
quent treatment failure [16]. In this paper, we show the
potential therapeutic use of gomesin in an experimental
infection of C. albicans.
Results
Evaluation of the antifungal activity of gomesin in vitro
The minimum inhibitory concentration (MIC) of gome-
sin in the isolate 78 and strain ATCC 90028 was 5.5
μM and 11 μM, respectively, while the MIC of Flucona-
zole in the isolate 78 and strain ATCC 90028 was 186
μM and > 1.5 mM, respectively. In addition, we
observed growth inhibition of the isolate 78 with the
combined treatment of 0.6 μM gomesin and 3.5 μM flu-
conazole. Growth inhibition of strain ATCC 90028 was
observed with the combined concentration of 1.3 μM
gomesin and 14.3 μM fluconazole (Table 1). Further-
more, the fractional inhibitory concentration index
(FICI) of the combination of gomesin and fluconazole
was 0.11 in isolate 78 and 0.19 in strain ATCC 90028
(Table 1).
Evaluation of the antifungal activity of gomesin in mice
with disseminated and vaginal candidiasis
Treatment with 5 mg/kg and 15 mg/kg of gomesin in
mice with disseminated candidiasis effectively reduced
the fungal burden of the kidneys, spleen and liver when
compared with the control group (PBS-treated mice)
(Figure 1A-C). Treatment with 10 mg/kg and 20 mg/kg
of fluconazole also effectively controlled the infection
(Figure 1A-C). Moreover, treatment of vaginal candidia-
sis with 0.2% and 0.5% gomesin and 2% miconazole
showed a significant decrease in colony forming units
(CFUs) when compared with vehicle treatment (control
group) (Figure 1D). The combination of gomesin and
fluconazole or miconazole did not result in a synergistic
effect.
Cytokine levels in kidneys of gomesin-treated mice
Treatment with gomesin and fluconazole significantly
increased the concentration of TNF-a, IFN-g and IL-6
in the kidneys compared to controls that were not
infected and not treated as well as controls that were
infected and treated with PBS (Figure 2).
Evaluation of the effect of antifungal drugs in
immunosuppressed mice with disseminated candidiasis
The group of infected animals that received PBS (con-
trol) reached 100% mortality on the fifteenth day after
infection. No statistically significant difference was
observed between the group treated with gomesin (5
mg/kg) and the group treated with fluconazole (20 mg/
kg), although there was an increase in survival during
the last treatment. Nonetheless, the combined treatment
of 5 mg/kg of gomesin and 20 mg/kg of fluconazole
produced a survival rate of 23% within 30 days after
infection, which was statistically significant. The control
groups that were not infected or those that received
PBS or 5 mg/kg of gomesin remained alive until the end
of the experiment (Figure 3).
In vivo toxicity
Gomesin administration did not alter the number of
leukocytes in the non-infected mice. However, when
specific cell populations were analysed, the number of
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neutrophils and eosinophils were increased, whereas the
number of lymphocytes was decreased. The administra-
tion of gomesin did not alter the haemoglobin levels.
Nevertheless, treatment with gomesin resulted in an
increase in the percentage of circulating reticulocytes.
Moreover, the administration of gomesin showed no
change in the levels of total bilirubin, direct and indir-
ect, as well as creatinine and gamma-GT (Table 2).
Biodistribution of radiolabeled gomesin
The biodistribution of gomesin labelled with techne-
tium-99 m was evaluated in the kidneys, spleen and
liver (Figure 4). The liver had the highest percentage of
radiolabeled peptide detected (60%), which persisted for
up to 24 h post-injection, whereas the kidneys showed a
radioactive peak at 120 min followed by a gradual
decrease during the following hours. The spleen was the
Table 1 Minimum inhibitory concentration (MIC) and fractional inhibitory concentration index (FICI) of gomesin and
fluconazole
MIC (μM) FICI
C. albicans (78) C. albicans
(ATCC 90028)
C. albicans (78) C. albicans
(ATCC 90028)
Gomesin 5.5 11 - -
Fluconazole * 186 - -
Gomesin + Fluconazole 0.6 + 3.5 1.3 + 14.3 0.11 0.19
* = not detected in up to 1.5 mM
Figure 1 Gomesin treatment of mice infected with C. albicans. Evaluation of the number of colony forming units (CFU) per gram of tissue of
the kidneys (A), spleen (B), liver (C) and vagina (D). The disseminated candidiasis was performed by intravenous injection of 3 × 105 yeasts
suspended in 100 μL of PBS and vaginal candidiasis was performed by inoculating 3 × 106 yeasts suspended in 20 μL of PBS. The treatment was
done one, three and six days after infection with C. albicans (strain 78). Animals were treated with different doses of gomesin (GOM), fluconazole
(FLUCO) and miconazole (MICO). As a control, infected animals received only PBS or cream (CREAM). * Indicates statistical significance (ANOVA
with post-Tukey test, P < 0.05).
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lowest of the organs tested (less than 5% detected) and
was stable for only 60 min after administration of tech-
netium-99 m-labelled gomesin, dropping to undetectable
levels after 120 min.
Discussion
Gomesin is an antimicrobial peptide isolated from hae-
mocytes of the spider Acanthoscurria gomesiana and
has a broad-spectrum of activity against bacteria, fungi,
protozoa and tumour cells [4,7,9,17,18]. The antifungal
activity of gomesin in vitro has previously been reported
[4,7]. However, the antifungal activity against clinical
Figure 2 Cytokine levels in kidneys . Cytokine levels were
evaluated in the kidneys of mice treated with gomesin (5 mg/kg)
and fluconazole (20 mg/kg). Non-infected and untreated animals
(NINF), as well as infected animals that received PBS, were used as
controls. * Indicates statistical significance (t-test, P < 0.05)
compared to the control INF.
Figure 3 Survival of immunosuppressed mice with
disseminated candidiasis treated with antifungal drugs. Animals
were treated with 100 mg/kg of cyclophosphamide and infected
with 103 yeasts of C. albicans (INF). The animals were treated with 5
mg/kg of gomesin (GOM), 20 mg/kg of fluconazole (FLUCO) or the
combination of 5 mg/kg gomesin and 20 mg/kg of fluconazole. As
controls, infected animals (NINF) received PBS and uninfected
animals received PBS and gomesin 5 mg/kg. * Indicates statistical
significance (Long-rank test, P < 0.05).
Table 2 Evaluation of the toxicity of the gomesin
treatment
NINF* NINF + GOM**
Leukocytes (mm3) 4637 ± 1114 4462 ± 1580
Neutrophils (mm3) 846 ± 288 1208 ± 388***
Eosinophils (mm3) 46 ± 46 135 ± 72***
Lymphocytes (mm3) 3744 ± 981 2660 ± 437***
Hemoglobin (g/dL) 13 ± 0.9 13 ± 0.5
Reticulocytes (%) 5.5 ± 0.7 9.3 ± 2.8***
Total Bilirubin (mg/dL) 0.48 ± 0.23 0.3 ± 0.1
Direct bilirubin (mg/dL) 0.35 ± 0.19 0.2 ± 0.1
Indirect bilirrubin (mg/dL) 0.13 ± 0.13 0.09 ± 0.009
Creatinine (mg/dL) 0.32 ± 0.09 0.34 ± 0.05
Gamma-GT (mg/dL) < 1 U/L < 1 U/L
* Non-infected mice
** Non-infected mice treated with gomesin (GOM)
*** p < 0.05
Rossi et al. BMC Microbiology 2012, 12:28
http://www.biomedcentral.com/1471-2180/12/28
Page 4 of 9
isolates of Candida albicans resistant to antifungal
drugs has not been studied. In this paper, we analysed
the antifungal activity of gomesin in vitro and in vivo
against a clinical strain of C. albicans (isolate 78), as
well as its biodistribution and toxicity in mice.
Our data showed that C. albicans (isolate 78) is resis-
tant to fluconazole up to 1.5 mM, but gomesin is effec-
tive against this strain at a lower concentration (MIC =
5.5 μM). This resistance to fluconazole is a common
cause of treatment failure [19]. A synergism between
gomesin and fluconazole against two isolates of Candida
albicans (78 and ATCC 90028) was demonstrated using
the FICI calculation method. The synergistic mechanism
of gomesin and fluconazole is not completely under-
stood, but studies with Cryptococcus neoformans
suggested that gomesin, through membrane permeabili-
sation, promotes an increased entry of fluconazole into
the fungal cytoplasm, which results in a better inhibition
of the ergosterol synthesis. In this way, fluconazole is
effective against C. neoformans at lower doses when
applied in combination with gomesin [7]. A similar phe-
nomenon was observed in murine melanoma cells
(B16F10-Nex2) treated with gomesin and the monoclo-
nal Mab A4M in vitro. The cytotoxicity of Mab A4M
was only detected in the presence of gomesin, after per-
meabilisation of the cell membrane allowed the entry
and action of the monoclonal antibody [9]. From these
studies, we hypothesised that gomesin facilitates the
entry of fluconazole in Candida albicans through mem-
brane permeabilisation.
The literature on the use of antimicrobial peptides in
the treatment of disseminated candidiasis is rather
scarce. A study of the HLF peptide (1-11) originated
from lactoferrin in immunosuppressed mice with
disseminated candidiasis showed that a single dose of
0.4 ng/kg, 24 h after infection, was able to significantly
reduce CFU in the kidneys [20]. ETD-151, an analogue
of heliomicin also has been shown to be particularly
effective against systemic candidiasis in comparison with
amphotericin B and several azoles [21]. Likewise, treat-
ment with gomesin proved to be effective against disse-
minated candidiasis. The peptide effectively reduced the
fungal burden in the kidneys, which is the highest trop-
ism organ for Candida. A similar effect was observed
with fluconazole; however, this drug has some toxic
effects and has selected resistance in Candida albicans
[19]. Therefore, the use of gomesin as a therapeutic may
be an alternative treatment for candidiasis because our
results show that it is non-toxic in mice. Unlike in vitro
treatment with gomesin and fluconazole, we have not
detected any the synergistic effect of treatment with
both drugs in vivo.
The treatment and prevention of recurrent vaginal
candidiasis includes the use of imidazoles and triazoles
as a first-line treatment, unless it is caused by a con-
firmed or suspected azole-resistant Candida strain. The
efficacy of both oral and local therapy is similar, but, the
local treatment presents several advantages, including a
reduction of adverse effects; however, local treatment is
contraindicated during pregnancy and breast feeding
[22]. In recent years, there has been a focus on both
understanding drug resistance to antifungal agents and
optimising therapy of Candida infections [23]. There
are no reports of topical treatment with antimicrobial
peptides against vaginal candidiasis. In this paper, we
are the first to describe an effective topical formulation
of an antimicrobial peptide that is able to reduce CFUs
count in an experimental vaginal candidiasis model. We
found that 0.2% and 0.5% gomesin cream reduced the
CFU on vaginas of the animals by 10 fold when com-
pared to control animals. Minor changes in the treat-
ment protocol with gomesin, either by increasing the
frequency or changing the doses, may potentially pro-
duce better results. Treatment with 2% miconazole
cream was also effective in controlling the CFUs of the
vaginas of the animals. However, it was necessary to use
a dose of miconazole that was at least four times higher
than the dose of gomesin to produce a similar effect. No
synergistic effect was observed after treatment with a
combination of gomesin and miconazole.
In addition to the direct action of AMPs on microor-
ganisms, either through membrane permeabilisation or
internal target interference [2], it has been reported that
some AMPs may possess an immunomodulatory func-
tion [3]. In order to verify if gomesin has such activity,
the concentrations of IFN-g, TNF-a and IL-6 were eval-
uated in the kidneys of mice that had been infected with
C. albicans and treated with this peptide. These
Figure 4 Biodistribution of gomesin. After administration of
radiolabeled gomesin (99mTc-HYNIC-gomesin), the liver, kidneys
and spleen were dissected at different time points to assess the
biodistribution of the peptide.
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cytokines, especially IL-6, activate neutrophils, which
play an essential role in the defence mechanism against
Candida[24]. We observed that treatment with 5 mg/kg
gomesin significantly increased the concentration of the
three cytokines analysed. A similar effect was also
observed with fluconazole treatment. The increase of
cytokine levels in the kidneys might help to control can-
didiasis through the activation of the host immune sys-
tem. This action appears to be similar to that observed
with another AMP, murine b defensin-2, which acts via
TLR4 and leads to the production of various cytokines,
such as IL-12 and IL-6, as well as chemokines [25].
However, we cannot dismiss the hypothesis that the
direct action of gomesin can trigger the release of
pathogen-associated molecular patterns, or PAMPs,
which would exacerbate the immune response of ani-
mals. This has been previously reported for the antimi-
crobial peptide human b defensin-2 [26]. The use of
antimicrobial peptides as immunomodulatory agents for
therapeutic application is an effervescent field in pro-
gress [27].
After verifying that the gomesin treatment was effec-
tive against disseminated candidiasis in healthy mice, we
decided to evaluate the activity of gomesin in immuno-
suppressed animals, as candidiasis is typically observed
in immunocompromised hosts [10]. Treatment with
gomesin (5 mg/kg) showed no significant increase in
survival compared to control animals. This suggests that
the direct action of gomesin was not sufficient to con-
trol the infection and that immunomodulatory action is
required to suppress the candidiasis. Treatment with flu-
conazole (20 mg/kg) also did not result in a significant
increase in the survival of treated animals as compared
to control animals. However, the combined treatment of
5 mg/kg gomesin and 20 mg/kg of fluconazole resulted
in 23% survival of mice 30 days after infection. This
could be due to gomesin facilitating the entry of fluco-
nazole into the yeast, thus leading to the survival of ani-
mals. Another hypothesis is that treatment with
fluconazole, being fungistatic, would allow time for
gomesin to act.
To evaluate whether gomesin could be used as a ther-
apeutic treatment for C. albicans infection, we per-
formed blood analyses to determine the toxicity of
gomesin in mice. No difference in the total number of
leukocytes was observed in animals treated with gome-
sin. However, the number of eosinophils in mice not
infected with Candida albicans but treated with gome-
sin was higher than the control group. The eosinophilia
caused by gomesin may be due to the induction of an
allergic response. Further experiments are needed in
order to evaluate this effect. We have also noticed that
gomesin treatment leads to a higher number of
neutrophils. This effect might be a consequence of the
induction of the pro-inflammatory response by gomesin,
which would stimulate the bone marrow to recruit neu-
trophils. However it is not currently known if these cells
are being recruited to the site of infection.
In addition, gomesin did not change the haemoglobin
levels, which suggests that this peptide was not toxic to
erythrocytes. However, the quantity of reticulocytes is
greater in treated animals, suggesting that the peptide
provokes an erythropoiesis compared to control animals
(non-gomesin treated). Perhaps treatment with gomesin
causes hypoxia in animals, thus increasing erythropoietin
[28]. Furthermore, gomesin was not nephrotoxic or hepa-
totoxic, as the bilirubin, creatinine, and Gamma GT levels
from treated animals are similar to the control group.
Therefore, gomesin seems to be non-toxic to mice.
In addition to the evaluation of toxicity, the biodistri-
bution of gomesin was performed to understand its
pharmacokinetics and therefore its therapeutic potential.
The biodistribution data revealed that the peptide
mainly accumulates in the liver, although it also accu-
mulates in the kidneys and spleen, within the first sev-
eral minutes after administration. This suggests a rapid
clearance from the circulation. The presence of gomesin
in the sites of infection might explain the reduction of
Candida albicans observed in our experiments. How-
ever, other studies are needed to monitor the excretion
of the peptide.
Conclusions
Gomesin was effective against Candida albicans infec-
tion in vitro and in vivo. Gomesin can be used as an
alternative treatment for candidiasis, either alone or in
combination with fluconazole. Although the mechanism
of action of gomesin is not fully understood, it has been
suggested that it directly acts on the fungal membrane
and/or stimulates the immune response against yeast
infection. Data presented in this study reinforces the
potential of gomesin as a therapeutic antifungal agent in
both humans and animals.
Methods
Antimicrobial compounds
The chemically synthesised gomesin was obtained from
GENEPEP (France) with 97% purity analysed by liquid
chromatography - mass spectrometry. Fluconazole was
obtained from Pfizer (Pfizer Inc., New York) and mico-
nazole from Janssen Pharmaceutica (Janssen-Pharma-
ceutica, Beerse). Gomesin and fluconazole were
dissolved in PBS for the in vivo assays and water for in
vitro tests. Miconazole was dissolved in PBS with 20%
dimethyl sulfoxide (DMSO) for incorporation into the
vaginal cream.
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Candida albicans strains
Two strains of Candida albicans were used: isolate 78
[29] and the isolate ATCC 90028. Periodically, isolate 78
was inoculated into mice in order to maintain its
virulence.
In vitro studies
The antifungal activity of antimicrobial compounds was
evaluated by using the protocol M-27A2, according to
the Clinical and Laboratory Standards Institute (CLSI)
[30]. Briefly, 80 μl of RPMI 1640 with 1.6 M MOPS pH
7 containing 104 yeast/mL of C. albicans in logarithmic
growth phase, were added to the wells of a polypropy-
lene 96-well plate containing 20 μl of serial two-fold
dilution of gomesin (starting at 44 μM), fluconazole
(starting at 1,488 μM) or the combination of gomesin
(starting at 11 μM) and fluconazole (starting at 115
μM). After 48 h of incubation at 37°C fungal growth
was evaluated by determining the absorbance at 595
nm. The lowest concentration that inhibited 100%
growth was considered the minimum inhibitory concen-
tration (MIC). The fractional inhibitory concentration
index (FICI) was determined following the methodology
described previously [31].
Animals
BALB/c mice (6- to 8-week-old males or females) were
bred at the Animal Facility at the Institute of Biomedical
Science of University of São Paulo, Department of
Immunology under specific pathogen-free conditions.
Food and water were given ad libitum. All animals were
handled in accordance with good animal practice as
defined by the relevant national animal welfare bodies
and all in vivo testing was approved by the Institutional
Animal Care and Use Committee of the University of
São Paulo, reference number: 87/42. For immunosup-
pression of animals, doses of 100 mg/kg cyclophospha-
mide were administered intraperitoneally 4 days and 1
day before infection with C. albicans, the third day after
infection and, from this point on, every 4 days until the
end of treatment [32]. The animals were kept in cages
lined with wood shavings and closed with autoclaved fil-
ter, and served autoclaved food and water in order to
maintain a sterile environment. Cages were exchanged
twice a week in laminar flow hoods. The animals were
considered anergic when the number of leukocytes was
found to be less than 100 cells/mm3 [33]. The vaginal
candidiasis model was developed by inducing the pseudo
oestrus phase by the subcutaneous administration of 0.5
mg of 17 beta-estradiol valerate (Sigma Chemicals, St
Louis), dissolved in sesame oil (Sigma Chemicals, St
Louis) 3 days before the vagina’s infection [34]. Swiss
mice were provided by the Animal Facility of IPEN-
CNEN for the biodistribution studies.
Infections
One colony of C. albicans (isolate 78) was selected from
the plate dishes and incubated in brain heart infusion
(Oxoid, England) at 37°C for 24 h with 200 rpm agita-
tion. The sediment obtained by centrifugation at 1500 g
for 5 min was washed three times in PBS and resus-
pended in 5 mL of PBS. The number of yeast per mL of
this suspension was determined with a Neubauer
chamber.
The disseminated candidiasis was induced by intrave-
nous injection of 3 × 105/100 μL of PBS and the immu-
nosuppressed model was induced by intravenous
injection of 103 yeasts suspended in 100 μL of PBS.
Vaginal candidiasis was induced by inoculating 3 × 106
yeasts suspended in 20 μL of PBS.
In vivo treatments
Mice with disseminated candidiasis were treated with
gomesin and fluconazole. The drugs were administered
intraperitoneally in a final volume of 500 μl at the fol-
lowing concentrations: gomesin (2.5 mg/kg, 5 mg/kg
and 15 mg/kg), fluconazole (10 mg/kg and 20 mg/kg)
and a combination of both (2.5 mg/kg to 5 mg/kg
gomesin and 10 mg/kg to 20 mg/kg fluconazole). For
mice with vaginal candidiasis, gomesin (0.02%, 0.2% and
0.5%), miconazole (2%) and a combination of both (0.2%
gomesin and 2% miconazole) were incorporated into a
vaginal cream (10% Wax self-nonionic emulsifier, 2%
mineral oil, 5% propylene glycol and 84% distilled water,
pH 4.5) for topical application. For all treatments, drugs
were administered 1, 3 and 6 days after infection with
C. albicans. An equivalent volume of PBS or cream was
administered to the control animals. To evaluate the
fungal burden, the kidneys, spleen, liver and vagina of
the mice were dissected aseptically on the seventh day
after infection, weighed and homogenised in 1 mL of
PBS. Aliquots of the homogenate (100 μl) were inocu-
lated on brain and heart infusion (Oxoid, England) con-
taining 2% agar. After incubation for 18 h at 37°C, the
number of CFUs was determined. The effectiveness of
treatment was determined by comparing the number of
CFUs per gram of tissue of treated animals with the
number of CFUs per gram of tissue of control animals
(untreated). For the survival curves, the animals were
monitored daily for 30 days.
Measurement of cytokines
The kidneys of animals infected with C. albicans and
treated with gomesin or fluconazole were dissected,
washed in PBS and homogenised with an electric tissue
homogeniser in 1 mL of PBS containing a cocktail of
protease inhibitors (Sigma Chemicals, St Louis). This
cocktail of protease inhibitors was composed of 1 μg/ml
of pepstatin A (aspartyl protease inhibitor), 4 mM
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benzamidine (seine protease inhibitor), 1 mM ethylene-
diaminetetraacetic acid acetic (metallo-protease inhibi-
tor) and 1 mM N-Ethylmaleimide (cysteine protease
inhibitor). Non-infected animals or animals infected and
not treated were used as controls. The concentrations of
IFN-g, TNF-a and IL-6 were evaluated on a flow cyt-
ometer (BD FACSCaliburTM, San José) using the kit
Cytometric Bead Array and Mouse Inflammation™ (BD,
San José) and the methodology described by the
manufacturer.
Blood analysis
Blood was collected by puncturing the brachial plexus of
anesthetised mice using EDTA (1%) as an anticoagulant
after 7 days of gomesin administration (15 mg/kg). Reti-
culocytes cells and leukocytes were counted by standard
methods. The haemoglobin concentration was deter-
mined using the modified Drabkin method. Blood sam-
ples were prepared on microscopic glasses, dried and
stained with May-Grünwald reagents for morphological
examination of the blood. The number of reticulocytes
was determined in blood smears stained with Supra
Vital New Methylene Blue. We also determined the
levels of bilirubin, creatinine and gamma GT biochemi-
cally using the Sims-Horm, Enzyme and Alkaline picrate
methods, respectively.
Evaluation of the biodistribution of radiolabelled gomesin
with technetium-99 m in mice
HYNIC-gomesin was manually synthesised by solid
phase methodology as described previously, except
that pyroglutamic acid was substituted for 6-hydrazino
nicotinamide (HYNIC) [6]. The HYNIC-gomesin con-
jugate was labelled with the radioisotope technetium-
99 m obtained from an alumina-based 99Mo/99mTc
generator, supplied by the Radiopharmacy Centre of
the Institute of Energetic and Nuclear Research
(IPEN/CNEN). Briefly, 20 mg of tricine and 5 mg of
ethylenediamine N,N’-diacetic acid (EDDA) were dis-
solved in 0.5 ml of 0.1 M PBS, previously nitroge-
nated. Ten micrograms of HYNIC-gomesin, 5 μl of 8.9
mM SnCl2·2H2O solution in 0.1 N HCl (nitrogen-
purged) and 500 μl of Na99mTcO4 was added to the
vial. The reaction was conducted by heating the solu-
tion at 100°C for 20 min in a water bath and then
allowing it to cool to room temperature. The pH of
the reaction mixture was 7 [35]. The product 99mTc-
HYNIC-gomesin (0.1 mL), with an approximate activ-
ity of 74 MBq (2 mCi), was administered to the tail
vein of the mice. The animals were sacrificed in a
CO2 chamber at 5, 30, 60, 120, 240, 360, and 1,440
min after injection of the radiolabeled gomesin. Six
animals were used for each time point. The kidneys,
spleen and liver of each animal was dissected and
transferred to tubes to measure radioactivity. The
radioactivity count was performed in the Gamma
Counter Shaft type NaI, using the same standard dose
in injected animals minus the radioactivity retained in
the site injection (tail). The uptake of radiolabeled
gomesin by each organ was calculated using the fol-
lowing equation: DI% = (CPM organ/standard CPM) ×
100), where%DI = percentage of the injected dose and
CPM = count per min [35].
Statistical analysis
ANOVA, with the post-Tukey test, was used to evaluate
the statistical significance of results obtained in all
experiments except the blood and survival analysis,
where the Students t-test and Log-rank test were used,
respectively. The differences between the results
obtained with treatment compared to the controls were
considered statistically significant when the p value was
less than 0.05.
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